Overview of treatment approaches to osteoporosis

Bente L. Langdahl

doi:10.1111/bph.15024

journal article Mar 20, 2020

Overview of treatment approaches to osteoporosis

Bente L. Langdahl

British Journal of Pharmacology Vol. 178 No. 9 pp. 1891-1906 · Wiley

View at Publisher Save 10.1111/bph.15024

Abstract

Efficient therapies are available for the treatment of osteoporosis. Anti‐resorptive therapies, including bisphosphonates and denosumab, increase bone mineral density (BMD) and reduce the risk of fractures by 20–70%. Bone‐forming or dual‐action treatments stimulate bone formation and increase BMD more than the anti‐resorptive therapies. Two studies have demonstrated that these treatments are superior to anti‐resorptives in preventing fractures in patients with severe osteoporosis. Bone‐forming or dual‐action treatments should be followed by anti‐resorptive treatment to maintain the fracture risk reduction. The BMD gains seen with bone‐forming and dual‐action treatments are greater in treatment‐naïve patients compared to patients pretreated with anti‐resorptive treatments. However, the antifracture efficacy seems to be preserved. Treatment failure will often lead to switch of treatment from orally to parentally administrated anti‐resorptives treatment or from anti‐resorptive to bone‐forming or dual‐action treatment. Osteoporosis is a chronic condition and therefore needs a long‐term management plan with a personalized approach to treatment.LINKED ARTICLESThis article is part of a themed issue on The molecular pharmacology of bone and cancer‐related bone diseases. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v178.9/issuetoc

Topics

No keywords indexed for this article. Browse by subject →

References

130

[1]

10.1136/bmj.i3365

[2]

10.1002/1529-0131(200101)44:1<202::aid-anr27>3.0.co;2-w

[3]

10.1002/jbmr.3420

[4]

Alexander S. P. H. "The Concise Guide to PHARMACOLOGY 2019/20: G protein‐coupled receptors" British Journal of Pharmacology (2019)

[5]

Alexander S. P. H. "The Concise Guide to PHARMACOLOGY 2019/20: Nuclear hormone receptors" British Journal of Pharmacology (2019)

[6]

Alexander S. P. H. "The Concise Guide to PHARMACOLOGY 2019/20: Catalytic receptors" British Journal of Pharmacology (2019)

[7]

10.1002/jbmr.1768

[8]

10.1007/s00198-012-1915-z

[9]

10.1210/en.2007-0270

[10]

10.1210/jc.2019-00192

[11]

10.1001/jamainternmed.2014.1232

[12]

10.1016/s0140-6736(96)07088-2

[13]

10.1056/nejmoa067312

[14]

10.1056/nejmoa031975

[15]

10.1002/jbmr.1494

[16]

10.1001/jama.296.24.2927

[17]

10.1210/jcem.85.11.6953

[18]

10.1210/jc.2018-00163

[19]

10.1016/s2213-8587(17)30138-9

[20]

10.1210/jc.2007-0711

[21]

10.1056/nejmoa1204061

[22]

Change in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials

Mary L Bouxsein, Richard Eastell, Li-Yung Lui et al.

Journal of Bone and Mineral Research 10.1002/jbmr.3641

[23]

10.1016/8756-3282(93)90092-o

[24]

10.1038/nrendo.2013.154

[25]

Risk of Subsequent Fracture After Low-Trauma Fracture in Men and Women

Jacqueline R. Center, Dana Bliuc, Tuan V. Nguyen et al.

JAMA 10.1001/jama.297.4.387

[26]

10.1359/jbmr.040325

[27]

10.1016/j.yrtph.2016.08.010

[28]

10.1210/jc.2014-1971

[29]

Romosozumab Treatment in Postmenopausal Women with Osteoporosis

Felicia Cosman, Daria B. Crittenden, Jonathan D. Adachi et al.

New England Journal of Medicine 10.1056/nejmoa1607948

[30]

Cosman F. "Romosozumab treatment in postmenopausal osteoporosis REPLY" New England Journal of Medicine (2017)

[31]

10.1002/jbmr.238

[32]

10.1016/j.mayocp.2016.10.009

[33]

Treatment Sequence Matters: Anabolic and Antiresorptive Therapy for Osteoporosis

Felicia Cosman, Jeri W Nieves, David W Dempster

Journal of Bone and Mineral Research 10.1002/jbmr.3051

[34]

10.1001/jama.280.24.2077

[35]

10.1056/nejmoa0808692

[36]

Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension

Steven R Cummings, Serge Ferrari, Richard Eastell et al.

Journal of Bone and Mineral Research 10.1002/jbmr.3337

[37]

Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

Steven R. Cummings, Javier San Martin, Michael R. McClung et al.

New England Journal of Medicine 10.1056/nejmoa0809493

[38]

10.1007/s00198-012-2093-8

[39]

10.1007/s00198-017-3906-6

[40]

10.1007/s00198-009-1077-9

[41]

Eisman J. A. "Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2‐year results from the DIVA study" The Journal of Rheumatology (2008)

[42]

10.1210/edrv-7-4-379

[43]

10.1016/0221-8747(84)90066-3

[44]

10.1001/jama.282.7.637

[45]

10.1359/jbmr.040117

[46]

Food and Drug Administration. (2019).FDA briefing document. Meeting of the Bone Reproductive and Urologic Drugs Advisory Committee.

[47]

10.1016/j.beem.2014.08.002

[48]

Ferrari S. Lewiecki E. M. Butler P. W.. Kendler D. L. Napoli N. HuangS. Crittenden B. Pannacciulli N. &Binkley N.(2018).Skeletal benefit/risk of long‐term denosumab therapy: A virtual twin analysis of fractures prevented to skeletal safety events observed.J Bone Min Res Abstract 1061.

[49]

10.1056/nejmoa035725

[50]

10.1007/bf00298608

Showing 50 of 130 references

Metrics

174

Citations

130

References

Details

Published: Mar 20, 2020
Vol/Issue: 178(9)
Pages: 1891-1906
License: View

Authors

B

Bente L. Langdahl

Endocrinology and Internal Medicine Aarhus University Hospital Aarhus Denmark

Cite This Article

Bente L. Langdahl (2020). Overview of treatment approaches to osteoporosis. British Journal of Pharmacology, 178(9), 1891-1906. https://doi.org/10.1111/bph.15024

Overview of treatment approaches to osteoporosis

You May Also Like